HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Moclobemide (Arima)

Subscribe to New Research on Moclobemide

A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.

Also Known As:

Arima; Aurorix; Manerix; 1A Brand of Moclobemide; Alphapharm Brand of Moclobemide; Alpharma Brand of Moclobemide; Apo-Moclobemide; Apotex Brand of Moclobemide; Aurorex; Azupharma Brand of Moclobemide; BC Brand of Moclobemide; Bull Brand of Moclobemide; Chem mart Brand of Moclobemide; Chem mart Moclobemide; DBL Moclobemide; Deprenorm; Faulding Brand of Moclobemide; Feraken; GenRX Moclobemide; Healthsense Brand of Moclobemide; Healthsense Moclobemide; Hexal Brand of Moclobemide; Hoffmann-La Roche Brand of Moclobemide; Kendrick Brand of Moclobemide; Merck dura Brand of Moclobemide; Moclamine; Moclix; Moclobamide; Moclobemid AZU; Moclobemid Stada; Moclobemid von ct; Moclobemid-1A Pharma; Moclobemid-Puren; Moclobemid-ratiopharm; Moclobeta; Moclodura; Moclonorm; Novo-Moclobemide; Novopharm Brand of Moclobemide; Nu-Moclobemide; Nu-Pharm Brand of Moclobemide; PMS-Moclobemide; Pharmascience Brand of Moclobemide; Rimoc; Ro 11-1163; Ro-11-1163; Roche Brand of Moclobemide; Stadapharm Brand of Moclobemide; Temmler Brand of Moclobemide; Terry White Chemists Brand of Moclobemide; Terry White Chemists Moclobemide; betapharm Brand of Moclobemide; ct-Arzneimittel Brand of Moclobemide; esparma Brand of Moclobemide; ratiopharm Brand of Moclobemide; AZU, Moclobemid; Apo Moclobemide; Hoffmann La Roche Brand of Moclobemide; Moclobemid 1A Pharma; Moclobemid Puren; Moclobemid ratiopharm; Moclobemid1A Pharma; Moclobemide 1A Brand; Moclobemide Alphapharm Brand; Moclobemide Alpharma Brand; Moclobemide Apotex Brand; Moclobemide Azupharma Brand; Moclobemide BC Brand; Moclobemide Bull Brand; Moclobemide Faulding Brand; Moclobemide Healthsense Brand; Moclobemide Hexal Brand; Moclobemide Kendrick Brand; Moclobemide Novopharm Brand; Moclobemide Nu-Pharm Brand; Moclobemide Pharmascience Brand; Moclobemide Roche Brand; Moclobemide Stadapharm Brand; Moclobemide Temmler Brand; Moclobemide betapharm Brand; Moclobemide ct-Arzneimittel Brand; Moclobemide esparma Brand; Moclobemide ratiopharm Brand; Moclobemide, Chem mart; Moclobemide, DBL; Moclobemide, GenRX; Moclobemide, Healthsense; Novo Moclobemide; NovoMoclobemide; Nu Moclobemide; Nu Pharm Brand of Moclobemide; NuMoclobemide; PMS Moclobemide; Ro 11 1163; Stada, Moclobemid; ct Arzneimittel Brand of Moclobemide; von ct, Moclobemid; Benzamide, 4-Chloro-N-(2-(4-morpholinyl)ethyl)-

Networked: 378 relevant articles (39 outcomes, 75 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Amides: 231
  - Benzamides: 80
    - Moclobemide: 378
- Carboxylic Acids: 83
  - Carbocyclic Acids
    - Benzoic Acids: 18
      - Benzamides: 80
        Moclobemide: 378

Experts

1.	Lin, Herng-Ching: 8 articles (02/2013 - 06/2006)
2.	Razvodovsky, Yury E: 6 articles (07/2014 - 01/2007)
3.	Kerr, William C: 4 articles (05/2014 - 11/2007)
4.	Chen, Chin-Shyan: 4 articles (05/2012 - 11/2008)
5.	Razvodovsky, Y E: 3 articles (03/2015 - 01/2007)
6.	Ren, Hong: 3 articles (07/2013 - 11/2007)
7.	Ye, Yu: 3 articles (02/2011 - 11/2007)
8.	Zhu, X P: 2 articles (01/2016 - 01/2016)
9.	Luan, R S: 2 articles (01/2016 - 01/2016)
10.	Yin, F: 2 articles (01/2016 - 01/2016)

Related Diseases

1.	Depressive Disorder (Melancholia) 01/01/1993 - "The antidepressant efficacy of both moclobemide and reference drugs was more pronounced in endogenous than in non-endogenous depression, whatever the severity." 09/01/1996 - "In summary, recent data which confirm and extend its comparative therapeutic efficacy and low potential for adverse effects have established moclobemide as an effective treatment in depressive disorders. " 01/01/1995 - "The evidence indicates that moclobemide is effective in typical severe depression with melancholia rather than being limited to less typical subtypes." 09/01/1996 - "Recent clinical trials and meta-analyses have confirmed the efficacy of moclobemide in the treatment of depressive disorders. " 01/01/1995 - "The efficacy of moclobemide has been demonstrated in psychotic and non-psychotic depression, in depression with and without melancholia, in endogenous depression (both unipolar and bipolar), in retarded depression and in agitated depression. "
2.	Phobic Disorders (Phobia) 09/01/1997 - "In this open, prospective, structured, naturalistic study of the efficacy of long-term treatment in social phobia 93 consecutive outpatients suffering from severe generalized or circumscribed social phobia (median Liebowitz Social Anxiety Scale score 83) and a high degree of concomitant psychiatric disease were administered treatment with moclobemide (712 +/- 75 mg/day at steady state). " 01/01/2001 - "Moclobemide produced a statistically significant, but clinically modest, degree of improvement in social phobia symptoms. " 01/01/1999 - "The efficacy of moclobemide has been shown in social phobia and the effect is more clear cut in patients with more severe symptoms. " 01/01/1994 - "Moclobemide was effective in both major components of social phobia (fear and avoidance). " 06/01/1996 - "The efficacy of moclobemide in social phobia has been demonstrated in short-term treatment for up to 12 weeks in three placebo-controlled studies. "
3.	Panic Disorder (Panic Attack) 10/01/1997 - "These data suggest moclobemide is a well tolerated and effective treatment for panic disorder." 04/01/2010 - "Improved statistical analysis of moclobemide dose effects on panic disorder treatment." 04/01/2010 - "We reanalyze, with complete data methods, a clinical trial previously reported using LOCF, comparing placebo and five dosage levels of moclobemide in the treatment of outpatients with panic disorder to illustrate the superiority of methods using repeated observations. " 06/01/2002 - "Patients (N = 452) with panic disorder were randomized to placebo or a fixed dose of moclobemide (75, 150, 300, 600, or 900 mg/day). " 06/01/2002 - "Interactive model of therapeutic response in panic disorder: moclobemide, a case in point."
4.	Major Depressive Disorder (Major Depressive Disorders) 01/01/1997 - "These results do not support moclobemide as an effective treatment of chronic fatigue syndrome in the absence of a major depressive disorder." 08/01/1999 - "Moclobemide in the treatment of major depressive disorder (DSM-3) following traumatic brain injury." 03/01/1997 - "These results provide supporting evidence of the comparable efficacy of moclobemide and fluoxetine and the better tolerability of moclobemide when used in the treatment of major depressive disorder." 03/01/1997 - "The objective of the present study was to compare the safety and efficacy of moclobemide versus fluoxetine in adult patients with major depressive disorder. " 10/01/2006 - "A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder."
5.	Alzheimer Disease (Alzheimer's Disease) 01/01/1992 - "Depression and senile dementia of the Alzheimer type: a role for moclobemide." 01/01/1995 - "Large placebo-controlled studies have shown the activity of moclobemide in the depression that accompanies dementia (such as senile dementia of Alzheimer type). " 08/01/2008 - "Recent randomized controlled trials demonstrated the efficacy of sertraline and moclobemide to treat depression in Alzheimer's disease. " 06/01/2006 - "Recent randomized controlled trials have demonstrated the efficacy of sertraline and moclobemide to treat depression in Alzheimer's disease. "

Related Drugs and Biologics

1.	Fluoxetine (Prozac)
2.	Clomipramine (Anafranil)
3.	Imipramine (Janimine)
4.	Sertraline (Zoloft)
5.	Serotonin (5 Hydroxytryptamine)
6.	Monoamine Oxidase (MAO)
7.	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
8.	brofaromine
9.	Maprotiline (Ludiomil)
10.	Phenelzine (Nardil)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Seat Belts (Seat Belt)